Recombinant Tick-Borne Encephalitis Virus NS1 protein produced in mammalian HEK293 human cells, incorporating a C-terminal 6x His-tag. Purity greater than 90%.
Tick-borne Encephalitis Virus NS1 protein
Tick-Borne Encephalitis Virus NS1 protein is produced entirely from human cell lines using state-of-the-art expression techniques, the same approach which NAC used to develop its well-received Dengue Virus NS1 serotypes and West Nile Virus NS1 protein.
The NAC Tick-Borne Encephalitis Virus NS1 protein has been manufactured in response to a need for a highly purified, concentrated protein for use in serological based diagnostic products. The antigen is in its native folding state, and possesses all post–translational modifications. This advanced approach results in a product which delivers optimal antigenicity due to its human origin.
The Tick-borne encephalitis virus (TBEV) is a Flavivirus which is transmitted to humans through a bite from an infected tick. Tick-borne encephalitis (TBE) is endemic in Europe and Asia with an average of 8,500 cases per year in Europe (https://wwwnc.cdc.gov/travel/page/yellowbook-home-2014/ ). TBE infected patients typically present with influenza-like symptoms and the disease is neuroinvasive often manifesting as meningitis, encephalitis or meningoencephalitis. Long-lasting or permanent neuropsychiatric sequelae are reported in 10 to 20% of patients.
Tick-Borne Encephalitis Virus NS1 is presented in a hexameric state and as usual this product is produced to The Native Antigen Company’s very high quality standards for lot-to-lot variation minimisation and product traceability. Please see the downloadable Certificate of Analysis for more information.
****SHIPPING NOTIFICATION: All NS1 products are shipped at ambient temperature. Extensive stability tests have shown no negative effects on antigen performance for 7 days of shipping including several freeze/thaw cycles. Should customers desire shipment on dry ice, this can be performed for an extra fee, please get in contact with us by phone or email.****